These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 15625429)

  • 21. Infliximab administered with shortened infusion times in a specialized IBD infusion unit: a prospective cohort study.
    Van Assche G; Vermeire S; Noman M; Amant C; Weyts E; Vleminckx A; Vermeyen MJ; Rutgeerts P
    J Crohns Colitis; 2010 Sep; 4(3):329-33. PubMed ID: 21122522
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety, satisfaction and cost savings of accelerated infusions of standard and intensified-dose infliximab for inflammatory bowel disease.
    Crane H; Wu N; Chan P; Nguyen P; Williams AJ; Ng W; Connor SJ
    Intern Med J; 2022 Dec; 52(12):2143-2149. PubMed ID: 34405958
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical experience with infliximab for Crohn's disease: the first 100 patients in Edmonton, Alberta.
    Sample C; Bailey RJ; Todoruk D; Sadowski D; Gramlich L; Milan M; Cherry R; Ma M; Lalor E; McKaigney J; Sherbaniuk R; Matic K; Switzer C; Fedorak RN
    Can J Gastroenterol; 2002 Mar; 16(3):165-70. PubMed ID: 11930194
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The extra burden of infliximab infusions in inflammatory bowel disease.
    Buisson A; Seigne AL; Dʼhuart MC; Bigard MA; Peyrin-Biroulet L
    Inflamm Bowel Dis; 2013 Oct; 19(11):2464-7. PubMed ID: 23942563
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Analysis of infliximab treated pediatric patients with Crohn disease in Hungary].
    Veres G; Szabó D; Várkonyi A; Tari B; Polgár M; B Kovács J; Horváth A; Tomsits E; Tokodi I; Bodánszky H; Dezsofi A; Szakos E; Vass N; Ruszinkó V; Kovács M; Müller KE; Arató A
    Orv Hetil; 2010 Jan; 151(5):179-83. PubMed ID: 20083466
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Premedication and infusion reactions with infliximab: results from a pediatric inflammatory bowel disease consortium.
    Jacobstein DA; Markowitz JE; Kirschner BS; Ferry G; Cohen SA; Gold BD; Winter HS; Heyman MB; Baldassano RN
    Inflamm Bowel Dis; 2005 May; 11(5):442-6. PubMed ID: 15867583
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rapid Infliximab Infusion in Children: A Multicenter Retrospective Cohort Study.
    Lev-Tzion R; Assa A; Yerushalmi B; Lahad A; Friedman M; Ledder O; Turner D
    J Pediatr Gastroenterol Nutr; 2017 Nov; 65(5):e101-e103. PubMed ID: 29064928
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety and cost of infliximab for the treatment of Belgian pediatric patients with Crohn's disease.
    De Greef E; Hoffman I; D'Haens G; Van Biervliet S; Smets F; Scaillon M; Dewit O; Peeters H; Paquot I; Alliet P; Arts W; Hauser B; Vermeire S; Van Gossum A; Rahier JF; Etienne I; Louis E; Coche JC; Mahachie John J; Van Steen K; Veereman G; ;
    Acta Gastroenterol Belg; 2012 Dec; 75(4):425-31. PubMed ID: 23402086
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Infusion administration billing for vedolizumab and infliximab in inflammatory bowel disease.
    Null K; Kumar V; Lissoos T; Luo M
    J Med Econ; 2018 Nov; 21(11):1102-1109. PubMed ID: 30101633
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of Rapid vs Standard Infliximab Infusions in the Pediatric Population.
    Rozette NA; Hellauer CM; McKee C; Vazifedan T; Gabriel CA; Dice JE; Yokois NU
    Inflamm Bowel Dis; 2018 Aug; 24(9):2007-2014. PubMed ID: 29788416
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Accelerated Infliximab Infusion: Safety, Factors Predicting Adverse Events, Patients' Satisfaction and Cost Analysis. A Cohort Study in IBD Patients.
    Mazzuoli S; Tricarico D; Demma F; Furneri G; Guglielmi FW
    PLoS One; 2016; 11(11):e0166443. PubMed ID: 27851772
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Infliximab as a novel therapy for pediatric ulcerative colitis.
    Mamula P; Markowitz JE; Brown KA; Hurd LB; Piccoli DA; Baldassano RN
    J Pediatr Gastroenterol Nutr; 2002 Mar; 34(3):307-11. PubMed ID: 11964959
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and Safety of Infliximab Therapy and Predictors of Response in Korean Patients with Crohn's Disease: A Nationwide, Multicenter Study.
    Choi CH; Song ID; Kim YH; Koo JS; Kim YS; Kim JS; Kim N; Kim ES; Kim JH; Kim JW; Kim TO; Kim HS; Kim HJ; Park YS; Park DI; Park SJ; Song HJ; Shin SJ; Yang SK; Ye BD; Lee KM; Lee BI; Lee SY; Lee CK; Im JP; Jang BI; Jeon TJ; Cho YK; Chang SK; Jeon SR; Jung SA; Jeen YT; Cha JM; Han DS; Kim WH;
    Yonsei Med J; 2016 Nov; 57(6):1376-85. PubMed ID: 27593865
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Accelerated infliximab infusions are safe and well tolerated in patients with inflammatory bowel disease.
    Clare DF; Alexander FC; Mike S; Dan G; Allan F; Lisa W; Peter HJ
    Eur J Gastroenterol Hepatol; 2009 Jan; 21(1):71-5. PubMed ID: 19060632
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The cost-effectiveness of infliximab in Crohn's disease.
    Smart C; Selinger CP
    Expert Rev Pharmacoecon Outcomes Res; 2014 Oct; 14(5):589-98. PubMed ID: 25138162
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Meta-analysis: rapid infliximab infusions are safe.
    Neef HC; Riebschleger MP; Adler J
    Aliment Pharmacol Ther; 2013 Aug; 38(4):365-76. PubMed ID: 23815183
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and tolerance of infliximab in children and adolescents with Crohn's disease.
    Lamireau T; Cézard JP; Dabadie A; Goulet O; Lachaux A; Turck D; Maurage C; Morali A; Sokal E; Belli D; Stoller J; Cadranel S; Ginies JL; Viola S; Huet F; Languepin J; Lenaerts C; Bury F; Sarles J;
    Inflamm Bowel Dis; 2004 Nov; 10(6):745-50. PubMed ID: 15626892
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Infliximab Biosimilar (Remsima™) in Therapy of Inflammatory Bowel Diseases Patients: Experience from One Tertiary Inflammatory Bowel Diseases Centre.
    Kolar M; Duricova D; Bortlik M; Hruba V; Machkova N; Mitrova K; Malickova K; Lukas M; Lukas M
    Dig Dis; 2017; 35(1-2):91-100. PubMed ID: 28147356
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Accelerated infliximab infusions for inflammatory bowel disease improve effectiveness.
    McConnell J; Parvulescu-Codrea S; Behm B; Hill B; Dunkle E; Finke K; Snyder K; Tuskey A; Cox D; Woodward B
    World J Gastrointest Pharmacol Ther; 2012 Oct; 3(5):74-82. PubMed ID: 23515325
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Costs of care for Crohn's disease following the introduction of infliximab: a single-centre UK experience.
    Sprakes MB; Ford AC; Suares NC; Warren L; Greer D; Donnellan CF; Jennings JS; Everett SM; Hamlin PJ
    Aliment Pharmacol Ther; 2010 Dec; 32(11-12):1357-63. PubMed ID: 21050238
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.